Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M65,344Revenue $M100,887Net Margin (%)2.1Altman Z-Score3.5
Enterprise Value $M76,797EPS $2.6Operating Margin %3.6Piotroski F-Score9
P/E(ttm)31.6Beneish M-Score-2.3Pre-tax Margin (%)3.1Higher ROA y-yY
Price/Book3.210-y EBITDA Growth Rate %24.4Quick Ratio0.5Cash flow > EarningsY
Price/Sales0.75-y EBITDA Growth Rate %20.7Current Ratio0.6Lower Leverage y-yY
Price/Free Cash Flow16.6y-y EBITDA Growth Rate %10.6ROA % (ttm)4.0Higher Current Ratio y-yY
Dividend Yield %--PEG1.5ROE % (ttm)10.3Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M729ROIC % (ttm)7.6Gross Margin Increase y-yY

Gurus Latest Trades with ESRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ESRXGlenn Greenberg 2015-03-31 Reduce-1.76%$80.71 - $87.62
($83.87)
$ 90.448%Reduce 14.51%3,495,539
ESRXWallace Weitz 2015-03-31 Reduce-0.61%$80.71 - $87.62
($83.87)
$ 90.448%Reduce 15.15%1,429,702
ESRXDodge & Cox 2015-03-31 Add0.4%$80.71 - $87.62
($83.87)
$ 90.448%Add 25.83%24,221,504
ESRXJoel Greenblatt 2015-03-31 Add0.31%$80.71 - $87.62
($83.87)
$ 90.448%Add 1814.84%493,798
ESRXHOTCHKIS & WILEY 2015-03-31 Add0.11%$80.71 - $87.62
($83.87)
$ 90.448%Add 21.31%2,003,400
ESRXCharles Brandes 2015-03-31 Reduce-0.07%$80.71 - $87.62
($83.87)
$ 90.448%Reduce 2.63%2,149,660
ESRXChris Davis 2015-03-31 Add0.06%$80.71 - $87.62
($83.87)
$ 90.448%Add 1.61%13,212,411
ESRXMario Gabelli 2015-03-31 Reduce$80.71 - $87.62
($83.87)
$ 90.448%Reduce 3.41%130,279
ESRXKen Fisher 2015-03-31 Add$80.71 - $87.62
($83.87)
$ 90.448%Add 0.99%534,029
ESRXJohn Keeley 2015-03-31 Reduce$80.71 - $87.62
($83.87)
$ 90.448%Reduce 1.74%30,458
ESRXGlenn Greenberg 2014-12-31 Reduce-2.33%$69.65 - $85.96
($78.34)
$ 90.4415%Reduce 17.94%4,088,652
ESRXChris Davis 2014-12-31 Add0.65%$69.65 - $85.96
($78.12)
$ 90.4416%Add 22.09%13,002,699
ESRXWallace Weitz 2014-12-31 Reduce-0.19%$69.65 - $85.96
($78.12)
$ 90.4416%Reduce 5.17%1,684,987
ESRXVanguard Health Care Fund 2014-12-31 Reduce-0.07%$69.65 - $85.96
($78.26)
$ 90.4416%Reduce 11.45%3,206,500
ESRXDodge & Cox 2014-12-31 Add0.06%$69.65 - $85.96
($78.26)
$ 90.4416%Add 4.22%19,248,979
ESRXHOTCHKIS & WILEY 2014-12-31 Reduce-0.05%$69.65 - $85.96
($78.26)
$ 90.4416%Reduce 10.80%1,651,500
ESRXCharles Brandes 2014-12-31 Reduce-0.04%$69.65 - $85.96
($78.26)
$ 90.4416%Reduce 2.05%2,207,728
ESRXMario Gabelli 2014-12-31 Reduce-0.04%$69.65 - $85.96
($78.12)
$ 90.4416%Reduce 45.53%134,879
ESRXWarren Buffett 2014-12-31 Sold Out -0.03%$69.65 - $85.96
($78.34)
$ 90.4415%Sold Out0
ESRXJoel Greenblatt 2014-12-31 Reduce-0.02%$69.65 - $85.96
($78.34)
$ 90.4415%Reduce 46.28%25,788
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ESRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ESRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MYERS WOODROW A JRDirector 2015-05-08Sell14,342$85.326view
BENANAV GARY GDirector 2015-05-04Sell10,000$87.393.49view
Wade Sara ESr. VP, Ch. Human Res. Off. 2015-05-01Sell12,000$86.534.52view
Norton David ASVP, Specialty & Supply Chain 2015-05-01Sell12,029$86.534.52view
Stettin Glen D.Sr. VP, Clin. Res. & New Sol. 2015-03-02Sell2,674$84.397.17view
Stettin Glen D.Sr. VP, Clin. Res. & New Sol. 2015-02-25Sell27,603$87.553.3view
Ebling Keith J.Exec. VP and General Counsel 2014-12-02Sell10,000$84.257.35view
Miller Steven BSr. VP & Chief Med. Officer 2014-12-01Sell4,896$83.578.22view
Stettin Glen D.Sr. VP, Clin. Res. & New Sol. 2014-11-28Sell10,800$82.969.02view
Stettin Glen D.Sr. VP, Clin. Res. & New Sol. 2014-11-21Sell10,874$81.510.97view

Press Releases about ESRX :

    Quarterly/Annual Reports about ESRX:

    News about ESRX:

    Articles On GuruFocus.com
    Chris Davis Adds to his Express Scripts Position May 15 2015 
    Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 
    20 Questions With David Rolfe May 08 2015 
    Analyzing Chris Davis' Top Holdings Apr 14 2015 
    Charles Brandes' Top Growth Stocks Apr 07 2015 
    CVS Health Corporation (CVS) Dividend Stock Analysis Apr 07 2015 
    UnitedHealth Group Is Ready For A Huge Pharmacy Deal Apr 06 2015 
    Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
    Vanguard Health Care Fund's Undervalued Stocks Apr 03 2015 
    UnitedHealth Planning Catamaran Corp’s Acquisition For $12.78 Billion Apr 02 2015 

    More From Other Websites
    Fight over hot new cholesterol drugs may be won in milligrams May 26 2015
    Upside plays in Express Scripts May 22 2015
    As Express Scripts Attacks Costs, Investors Will Profit May 21 2015
    Coverage initiated on Express Scripts by Robert W. Baird May 20 2015
    Annual Healthcare Cost For Family Of Four Now At $24,671 May 19 2015
    How much do Americans spend on drugs? May 13 2015
    More M&A Could be Coming for This Healthcare ETF May 13 2015
    Drug 'super spenders' rack up $52 billion last year May 13 2015
    5 Hated Stocks That Could Pop in May May 13 2015
    Your prescriptions costs what? May 13 2015
    Express Scripts Research Highlights $52 Billion Challenge for U.S. Healthcare System May 13 2015
    Express Scripts Research Highlights $52 Billion Challenge for U.S. Healthcare System May 13 2015
    Number of Americans using $100,000 in medicines triples -Express Scripts May 12 2015
    500,000 Americans spend $50K on medicine each year May 12 2015
    Drug Costs Top $50K A Year For Half Million Americans May 12 2015
    EXPRESS SCRIPTS HOLDING CO. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 08 2015
    Cancer drug spending hit $100 billion in 2014. Here’s why it’ll soon be much higher May 08 2015
    EXPRESS SCRIPTS HOLDING CO. Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 05 2015
    Express Scripts Goes On The Aggressive To Bargain For Lower Cancer Drug Prices May 05 2015
    SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health May 05 2015
    SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health May 05 2015
    Express Scripts draws call buyers May 05 2015
    Express Scripts meets 1Q profit forecasts Apr 28 2015
    Express Scripts Announces 1st Quarter Results; Announces New Credit Agreement; Narrows 2015 Guidance... Apr 28 2015
    Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective... Apr 21 2015
    Express Scripts climbs as Walgreens states interest in deals Apr 09 2015
    Express Scripts Holding Company Announces First Quarter 2015 Earnings Conference Call Apr 08 2015
    UnitedHealth to buy pharmacy benefit firm Catamaran for $12.8 billion Mar 30 2015
    U.S. Prescription Drug Spending Increased 13.1 Percent in 2014, Driven by Hepatitis C and Compounded... Mar 10 2015
    Express Scripts rises after-hours following 4Q report Feb 23 2015
    Express Scripts Announces 4th Quarter Results; Provides Initial 2015 Earnings Guidance Feb 23 2015
    Express Scripts tops Street 4Q forecasts Feb 23 2015
    Express Scripts beats Street 4Q forecasts Feb 23 2015
    AstraZeneca to pay $7.9 million over kickback allegations Feb 11 2015
    AbbVie reports better-than-expected 4Q on Humira sales Jan 30 2015
    German insurers win discounts on Gilead's Sovaldi Jan 24 2015
    Aetna picks Gilead Sciences hepatitis C drugs over AbbVie's Jan 16 2015
    Insight - Big Pharma faces up to new price pressure from aggressive insurers Jan 15 2015
    Big Pharma faces up to new price pressure from aggressive insurers Jan 15 2015
    Pharma and biotech on a roll as drug approvals hit 18-year high Jan 02 2015
    Pharma and biotech on a roll as drug approvals hit 18-year high Jan 01 2015
    US STOCKS-Dow ends above 18k for first time on strong GDP report Dec 23 2014
    Dow tops 18,000 as market reaches new highs Dec 23 2014
    US STOCKS-GDP lifts Dow over 18k; biotechs have worst day since April Dec 23 2014
    US STOCKS-Futures edge up after latest record; data on tap Dec 23 2014
    US STOCKS-Dow, S&P end at records in 4th straight day of gains for Wall St Dec 22 2014
    Express Scripts turns to AbbVie in huge hepatitis C deal Dec 22 2014
    US STOCKS-Wall St up for fourth straight day; S&P ends at record Dec 22 2014
    US stock indexes drift higher in afternoon trading Dec 22 2014
    US STOCKS-Wall St on track for four-day rally; tech lifts Dow Dec 22 2014
    US STOCKS-Wall St edges up after three-day run; tech lifts Dow Dec 22 2014
    US stock indexes drift higher in midday trading Dec 22 2014
    Stocks mostly higher in morning trading, extending rally Dec 22 2014
    US STOCKS-Wall St flat after three-day run; Gilead drags Dec 22 2014
    US STOCKS-Wall St edges up after three-day run; Gilead slumps Dec 22 2014
    US STOCKS-Wall St set to open up after three-day run; data on tap Dec 22 2014
    US STOCKS-Futures advance after three-day rally; data on tap Dec 22 2014
    US STOCKS-Futures climb after three-day run Dec 22 2014
    Express Scripts and AbbVie Make Hepatitis C Cure Available to Millions of Patients in Need Dec 22 2014
    Express Scripts Chief Financial Officer Cathy Smith to leave Dec 16 2014
    Express Scripts Initiates Chief Financial Officer Transition Process; Increases Authorization of... Dec 15 2014
    Many Americans on Long-Term Painkillers Take Potentially Fatal Drug Combinations Dec 09 2014
    Berkshire invests in Express Scripts, makes confidential disclosure Nov 14 2014
    Express Scripts to Present at the Credit Suisse Healthcare Conference Nov 05 2014
    Express Scripts meets 3Q profit forecasts Oct 28 2014
    Express Scripts Announces 3rd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point Oct 28 2014
    2015 Express Scripts Medicare Prescription Drug Plans Earn CMS 4-Star Quality and Performance Rating Oct 15 2014
    GSK gets a lift as Express Scripts reinstates lung drug Advair Aug 04 2014
    GSK gets a lift as Express Scripts reinstates lung drug Advair Aug 04 2014
    GSK gets a lift as Express Scripts reinstates lung drug Advair Aug 04 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Srichardson
    ReplySrichardson - 9 months ago
    How do you see the % of Total Asset for a position in a guru portfolio?
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK